Company profile for CytoMed Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Incorporated in 2018, CytoMed is a biotech company spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector, and focused on translating its proprietary technologies into cell-based immunotherapy cancer treatments. The development of these novel technologies was inspired by the clinical success of chimeric antigen receptor-modified T (CAR-...
Incorporated in 2018, CytoMed is a biotech company spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector, and focused on translating its proprietary technologies into cell-based immunotherapy cancer treatments. The development of these novel technologies was inspired by the clinical success of chimeric antigen receptor-modified T (CAR-T) cells in treating hematological malignancies and introduces solutions for the clinical limitations and commercial challenges inherent in extrapolating the CAR-T principle into treatments for solid tumors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Singapore
Address
Address
1 Commonwealth Lane #08-22, 149544
Telephone
Telephone
+607-3824911
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/18/3189932/0/en/CytoMed-Therapeutics-Completes-Acquisition-of-T-Cell-Technology-from-UK-to-Treat-Cancers-in-China-and-India.html

GLOBENEWSWIRE
18 Nov 2025

https://www.globenewswire.com/news-release/2025/10/22/3171038/0/en/CytoMed-Therapeutics-Chairman-Increases-Effective-Holdings-to-21-95.html

GLOBENEWSWIRE
22 Oct 2025

https://www.globenewswire.com/news-release/2025/10/14/3166116/0/en/CytoMed-makes-cash-bid-for-potential-acquisition-of-TC-BioPharm-Limited-s-relevant-assets.html

GLOBENEWSWIRE
14 Oct 2025

https://www.globenewswire.com/news-release/2025/10/02/3160232/0/en/CytoMed-Therapeutics-Announces-Publication-of-Collaborative-Research-with-The-University-of-Texas-MD-Anderson-Cancer-Center-Demonstrating-the-Potential-of-Allogeneic-%CE%B3%CE%B4-T-Cells-in-.html

GLOBENEWSWIRE
02 Oct 2025

https://www.globenewswire.com/news-release/2025/08/28/3140830/0/en/Update-on-recent-acquisition-CytoMed-Therapeutics-expands-into-auto-immune-diseases-building-on-its-recent-cord-blood-bank-acquisition.html

GLOBENEWSWIRE
28 Aug 2025

https://www.globenewswire.com/news-release/2025/08/19/3135384/0/en/CytoMed-Therapeutics-Limited-Announces-At-the-Market-ATM-Offering-Program.html

GLOBENEWSWIRE
18 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty